Candriam S.C.A. Sells 105,374 Shares of Mirum Pharmaceuticals, Inc. $MIRM

Candriam S.C.A. cut its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 18.5% in the 1st quarter, Holdings Channel.com reports. The firm owned 464,216 shares of the company’s stock after selling 105,374 shares during the quarter. Candriam S.C.A.’s holdings in Mirum Pharmaceuticals were worth $42,884,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Janus Henderson Group PLC raised its holdings in Mirum Pharmaceuticals by 21.4% during the 4th quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company’s stock worth $479,050,000 after buying an additional 1,067,722 shares during the period. State Street Corp boosted its holdings in shares of Mirum Pharmaceuticals by 59.2% in the fourth quarter. State Street Corp now owns 2,143,992 shares of the company’s stock valued at $169,354,000 after buying an additional 797,088 shares during the period. Wellington Management Group LLP increased its position in shares of Mirum Pharmaceuticals by 566.8% during the third quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock worth $57,965,000 after acquiring an additional 672,118 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of Mirum Pharmaceuticals by 709.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 612,318 shares of the company’s stock worth $44,889,000 after acquiring an additional 536,674 shares in the last quarter. Finally, Voloridge Investment Management LLC raised its holdings in shares of Mirum Pharmaceuticals by 2,116.6% during the third quarter. Voloridge Investment Management LLC now owns 389,574 shares of the company’s stock worth $28,560,000 after acquiring an additional 371,999 shares during the period.

Analysts Set New Price Targets

Several equities research analysts recently commented on MIRM shares. Stifel Nicolaus set a $136.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. Raymond James Financial reiterated a “strong-buy” rating and set a $165.00 target price on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Monday, June 15th. Wall Street Zen lowered Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Morgan Stanley upped their price objective on Mirum Pharmaceuticals from $140.00 to $150.00 and gave the stock an “overweight” rating in a research report on Thursday, June 11th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Mirum Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $143.40.

Insider Transactions at Mirum Pharmaceuticals

In other news, SVP Jolanda Howe sold 2,721 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $120.00, for a total value of $326,520.00. Following the completion of the transaction, the senior vice president owned 3,114 shares in the company, valued at $373,680. This trade represents a 46.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $95.84, for a total value of $2,875,200.00. Following the completion of the transaction, the chief executive officer owned 194,309 shares of the company’s stock, valued at $18,622,574.56. The trade was a 13.37% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 65,315 shares of company stock worth $6,991,928 in the last three months. Insiders own 8.32% of the company’s stock.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM stock opened at $122.13 on Friday. The company’s fifty day simple moving average is $106.49 and its 200-day simple moving average is $97.73. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 1.28. The firm has a market cap of $7.45 billion, a PE ratio of -8.97 and a beta of 0.48. Mirum Pharmaceuticals, Inc. has a 12 month low of $50.25 and a 12 month high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The business had revenue of $159.88 million during the quarter, compared to the consensus estimate of $148.21 million. During the same period last year, the business posted ($0.30) EPS. The firm’s revenue for the quarter was up 43.3% on a year-over-year basis. Equities research analysts expect that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.